BR112023015561A2 - Compostos imunoestimuiladores e conjugados - Google Patents

Compostos imunoestimuiladores e conjugados

Info

Publication number
BR112023015561A2
BR112023015561A2 BR112023015561A BR112023015561A BR112023015561A2 BR 112023015561 A2 BR112023015561 A2 BR 112023015561A2 BR 112023015561 A BR112023015561 A BR 112023015561A BR 112023015561 A BR112023015561 A BR 112023015561A BR 112023015561 A2 BR112023015561 A2 BR 112023015561A2
Authority
BR
Brazil
Prior art keywords
antibody
drug conjugates
tumor
immunostimulating
conjugates
Prior art date
Application number
BR112023015561A
Other languages
English (en)
Inventor
Alyson Smith
Scott Neumann Christopher
David Ferguson
Kung-Pern Wang
J Gardai Shyra
Original Assignee
Univ Minnesota
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Seagen Inc filed Critical Univ Minnesota
Publication of BR112023015561A2 publication Critical patent/BR112023015561A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

compostos imunoestimuiladores e conjugados. a presente divulgação fornece, inter alia, conjugados anticorpo-fármaco que são úteis no tratamento de várias doenças, tal como câncer. os conjugados anticorpo-fármaco podem ser configurados para induzir respostas específicas do sítio do tumor, incluindo imunoestimulação do microambiente tumoral, enquanto limitam os efeitos fora do alvo e sistêmicos. em certas modalidades divulgadas neste documento, os conjugados anticorpo-fármaco são configurados para liberar cargas úteis após internalização por células imunes, cancerígenas ou associadas a tumores.
BR112023015561A 2021-02-03 2022-02-03 Compostos imunoestimuiladores e conjugados BR112023015561A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163145367P 2021-02-03 2021-02-03
PCT/US2022/015157 WO2022170002A1 (en) 2021-02-03 2022-02-03 Immunostimulatory compounds and conjugates

Publications (1)

Publication Number Publication Date
BR112023015561A2 true BR112023015561A2 (pt) 2023-11-14

Family

ID=80445928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023015561A BR112023015561A2 (pt) 2021-02-03 2022-02-03 Compostos imunoestimuiladores e conjugados

Country Status (13)

Country Link
US (1) US20240165251A1 (pt)
EP (1) EP4288109A1 (pt)
JP (1) JP2024506300A (pt)
KR (1) KR20230152679A (pt)
CN (1) CN116847886A (pt)
AR (1) AR124812A1 (pt)
AU (1) AU2022216598A1 (pt)
BR (1) BR112023015561A2 (pt)
CA (1) CA3206244A1 (pt)
IL (1) IL304565A (pt)
MX (1) MX2023009113A (pt)
TW (1) TW202241522A (pt)
WO (1) WO2022170002A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081237A1 (en) * 2021-11-03 2023-05-11 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
WO2024030577A1 (en) * 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
PT964702E (pt) 1996-08-02 2006-12-29 Ortho Mcneil Pharm Inc Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2007011968A2 (en) 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
EP1988896A4 (en) * 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
CN101541834A (zh) 2006-10-06 2009-09-23 武田药品工业株式会社 癌症的预防和/或治疗剂
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US8614301B2 (en) 2007-11-14 2013-12-24 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of treating cancer using anti CD24 antibodies
RU2755066C2 (ru) 2010-06-08 2021-09-13 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
US9045542B2 (en) 2011-08-29 2015-06-02 Baylor Research Institute Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)
HUE053362T2 (hu) 2012-04-27 2021-06-28 Novo Nordisk As Emberi CD30-ligand antigént kötõ fehérjék
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
NZ717668A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2015077826A1 (en) 2013-11-27 2015-06-04 Welcome Receptor Antibodies Pty Ltd Marker of cell death
AR100137A1 (es) * 2014-04-22 2016-09-14 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina
US9884866B2 (en) * 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
EP3900742B1 (en) 2014-09-11 2024-05-15 Seagen Inc. Targeted delivery of tertiary amine-containing drug substances
AU2016322934A1 (en) 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
US10730871B2 (en) * 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2017210844A1 (en) 2016-06-06 2017-12-14 Asclepiumm Taiwan Co., Ltd Dsg2 monoclonal antibody and use thereof
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2018123949A1 (ja) 2016-12-28 2018-07-05 国立医薬品食品衛生研究所長が代表する日本国 抗クローディン－２モノクローナル抗体
WO2018134389A1 (en) 2017-01-23 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating infections
EP3574018A4 (en) * 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
US20210284750A1 (en) * 2017-04-14 2021-09-16 Bolt Biotherapeutics, Inc. Immunoconjugate Synthesis Method
US11655307B2 (en) 2017-05-30 2023-05-23 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
EP3710059A1 (en) * 2017-11-14 2020-09-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
KR102078775B1 (ko) 2017-11-29 2020-02-19 서울대학교산학협력단 항-ros1 항체 및 그의 용도
WO2020056192A1 (en) * 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Antibody conjugates of toll-like receptor agonists
WO2020190760A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting cea
MA55615A (fr) 2019-04-10 2022-02-16 Regeneron Pharma Anticorps humains qui se lient au ret et leurs procédés d'utilisation
CN114206936A (zh) 2019-06-14 2022-03-18 2赛文缇生物公司 用于治疗癌症的组合物和方法

Also Published As

Publication number Publication date
MX2023009113A (es) 2023-08-10
CN116847886A (zh) 2023-10-03
CA3206244A1 (en) 2022-08-11
AR124812A1 (es) 2023-05-10
EP4288109A1 (en) 2023-12-13
TW202241522A (zh) 2022-11-01
AU2022216598A1 (en) 2023-08-03
IL304565A (en) 2023-09-01
WO2022170002A1 (en) 2022-08-11
KR20230152679A (ko) 2023-11-03
JP2024506300A (ja) 2024-02-13
US20240165251A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
BR112023015561A2 (pt) Compostos imunoestimuiladores e conjugados
CL2020002053A1 (es) Métodos y composiciones para polarización de macrófagos.
CY1122855T1 (el) Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου
CY1124628T1 (el) Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως
PE20170517A1 (es) Conjugados de anticuerpo-farmaco-anti-ptk7
BR112012023621A2 (pt) composição dos peptídeos associados a tumor e vacina anticâncer relacionada para o tratamento do câncer gástrico e outros cânceres
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PE20150091A1 (es) Anticuerpos anti-sez6 y metodos de empleo
BR112018069133A2 (pt) composições e métodos para penetração direcionada de partículas, distribuição, e resposta em tumores cerebrais malignos
PE20191539A1 (es) Conjugados anticuerpo-droga para ablacion de celulas madre hematopoyeticas
NZ591882A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
MX369664B (es) Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.
CY1121667T1 (el) Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
BR112017015582A2 (pt) conjugados de anticorpo-urease para propósitos terapêuticos
CY1124266T1 (el) Συζευγματα αντισωματος-φαρμακου κατα toy met
EA201691384A3 (ru) Конструкции варианта sirp-альфа и их применение
EP3826663A4 (en) ADMINISTRATION OF SIALIDASE TO CANCER CELLS, IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT
ECSP23025680A (es) Moléculas de unión a b7-h4 terapéuticas
CO2024003299A2 (es) Conjugado anticuerpo-fármaco anti-cd37
MX2023008803A (es) Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.
CL2022003411A1 (es) Conjugados anticuerpo biespecífico-fármaco dirigidos a egfr y muc1 y sus usos
BR112023014128A2 (pt) Conjugados de anticorpo-fármaco imunomodulatórios